DEC 23, 2019 8:40 AM PST

Novel Drug for Treating Insomnia

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration (FDA) has approved DAYVIGO™ (lemborexant) in 5 mg and 10 mg for the treatment of insomnia among adult patients with insomnia. Insomnia is a difficult sleeping condition characterized by the inability to sleep or maintain sleep.

Learn more about insomnia:

Approval for DAYVIGO comes after two randomized and double-blined Phase 3 studies that evaluated the efficacy of the drug in comparison to the placebo. One study noted results for one month and the other study continued the comparison for six months. Despite good results, FDA encourages DAYVIGO to be placed under the controlled substances and such is currently being evaluated by the U.S. Drug Enforcement Administration (DEA) before being commercially available.

"We believe the approval of DAYVIGO is particularly exciting because it is the first FDA-approved medication to report safety data over a 12-month period along with sleep onset and sleep maintenance efficacy data over a six-month period in a pivotal clinical study," said Lynn Kramer, MD, Chief Clinical Officer, Neurology Business Group, Eisai Pharmaceutical. "We look forward to making this new therapeutic option available to the millions of patients who suffer with insomnia."

DAYVIGO was developed by the pharmaceutical drug company, Eisai.

"Insomnia disorder is a chronic condition that has a variety of potential negative impacts and long-term consequences for health and well-being,"2 said Russell Rosenberg, PhD, D.ABSM, a principal investigator in the DAYVIGO clinical studies and former Chairman of the Board of the National Sleep Foundation. "The clinical trials provide evidence that DAYVIGO may improve patients' ability to fall asleep and stay asleep."

In both studies, the most commonly reported side-effects that led to discontinuation was because somnolence and nightmares. In addition, the effects of DAYVIGO at the beginning of treatment were generally the same as the endpoint.

The drug was not associated with rebound insomnia following discontinuation or any withdrawal effects. However, DAYVIGO was associated with dose-dependent worsening effects on attention and memory compared to the placebo.

"DAYVIGO is an important addition to Eisai's rapidly growing neurology portfolio and underscores our leadership in neuroscience," said Ivan Cheung, Chairman and CEO, Eisai Inc. and Global President, Neurology Business Group, Eisai Co., Ltd. "Our commitment to patients and their families drives our relentless pursuit of innovative healthcare solutions."

Source: FDA

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
FEB 10, 2020
Cancer
FEB 10, 2020
New hope for KRAS-mutant pancreatic cancers
A study published recently in the journal Cancer Research showcases the findings from new research on pancreatic cancer. The study was led by Frank Mc
FEB 08, 2020
Drug Discovery & Development
FEB 08, 2020
Drug Targets Brain-Eating Amoebas
Brain-eating amoebas lead to high rates of mortality as a result of encephalitis. In fact, more than 95% of people who develop the infection will die. Unfo
FEB 21, 2020
Health & Medicine
FEB 21, 2020
Should You Really be Scared of the Coronavirus?
As of February 21st, the death toll for coronavirus reached 2,250, 55,707 currently infected, of which 12,066 (22%) are in a serious or critical condition.
FEB 20, 2020
Drug Discovery & Development
FEB 20, 2020
Antibiotics for Superbug Infections?
Antibiotics for superbug infections? A study published in the Proceedings of the National Academy of Sciences claims that a combination of compounds can ta
MAR 14, 2020
Drug Discovery & Development
MAR 14, 2020
Mental Heath Implications of a Controversial Acne Drug
Isotretinoin is a highly effective marketed treatment for acne that has long been believed to have an association with teen suicide and depression. Now, a
MAR 29, 2020
Neuroscience
MAR 29, 2020
Anti-Inflammatory Injection May Prevent Memory Loss from Alzheimer's
Around 5.5 million people in the US suffer from Alzheimer’s Disease. Now, research has found that reducing the bod...
Loading Comments...